Results 181 to 190 of about 50,169 (235)

Targeting the Werner syndrome protein in microsatellite instability cancers: mechanisms and therapeutic potential. [PDF]

Clin Exp Med
Chen S, Wang Z, Cao Z, Xu M, Zhang Y.
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. [PDF]

Int J Mol Sci
Awosika JA, Gulley JL, Pastor DM.
europepmc   +1 more source

A Network‐Based Association of IBD and Colorectal Cancer Using Proteomics Data

PROTEOMICS – Clinical Applications, Volume 20, Issue 2, March 2026.
ABSTRACT Background Colorectal cancer (CRC) is a major cause of morbidity and mortality, with chronic inflammation from inflammatory bowel disease (IBD) representing a well‐established risk factor. Clarifying shared molecular mechanisms may facilitate early detection and prevention strategies.
Jaiya Dhami, Swarnima Kollampallath Radhakrishnan, Dominic Russ, Sudip Mondal, Abdulrahman Alzarooni, Laura Bravo Merodio, Niharika A. Duggal, Ruchi Gupta, Animesh Acharjee   +8 more
wiley   +1 more source

Immunotherapy Plus Surgery Improves Survival in Microsatellite Instability-High Colon Cancer with Isolated Peritoneal Metastases. [PDF]

Cancers (Basel)
Metzger DA, Chahal Y, Watman O, Li Y, Pigazzi A, Siolas D, Jafari MD.   +6 more
europepmc   +1 more source

Artificial Intelligence in Gastrointestinal Disease Diagnosis: A Systematic Review of Endoscopy, Histology, and Radiology Applications

WIREs Data Mining and Knowledge Discovery, Volume 16, Issue 1, March 2026.
Overview of artificial intelligence applications in gastrointestinal disease diagnosis across multiple imaging modalities. The workflow illustrates the progression from image acquisition through preprocessing, feature extraction/learning, and classification/segmentation to clinical applications.
Sameena Pathan, Alen Shahini, Massimo Salvi, Tanweer Ali, Jovita Relasha Lewis, Filippo Molinari, U. Rajendra Acharya   +6 more
wiley   +1 more source

CircCLMP Suppresses Anti-Tumor Immunity by Inhibiting Activation of IRF3 and Interferon Response in Microsatellite Instability-high Endometrial Cancer. [PDF]

Int J Biol Sci
Wen W, Yuan L, Guo P, Zhao X, Chen L, Liu S, Fan H, Lin L, Pan Y, Chen S, Xiao Y, Liu P, Wang D, Jiang H, Wang W, Zhang C, Yao S.   +16 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Mismatch Repair Deficiency in Gliomas: A Rare Insight into Microsatellite Instability and Its Diagnostic Implications. [PDF]

Asian J Neurosurg
Rajendiran I, Ahluwalia C, Shankar KB, Arora S, Ahuja S.   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source